Tag

The Long Run

12
Feb
2019

The Immune Sequencing Frontier (Take 2): Harlan and Chad Robins on The Long Run

Today’s guests on The Long Run are Harlan and Chad Robins. They are brothers and co-founders of Seattle-based Adaptive Biotechnologies. Chad is the CEO, and Harlan is the head of innovation. Harlan is also a faculty member at the Fred Hutchinson Cancer Research Center just down the street from Adaptive. Senior people in pharma R&D are quite familiar with Adaptive....
Read More
30
Jan
2019

Finding a Way in Genomic Diagnostics: Bonnie Anderson of Veracyte on The Long Run

Bonnie Anderson is today’s guest on The Long Run. Bonnie is the CEO of Veracyte. It’s a genomic diagnostics company in South San Francisco. The company markets a line of tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte got started in 2008. Bonnie, as co-founder and CEO, was recruited by Kleiner Perkins Caufield & Byers and a...
Read More
2
Jan
2019

From Merck Fast Track to Computer Chem Frontier: Karen Akinsanya on The Long Run

Today’s guest on The Long Run is Karen Akinsanya. Karen is the chief biomedical scientist at Schrodinger. The New York-based company is a leader in computational chemistry for drug discovery. The company is privately held, and not a household name. But some wealthy and powerful people know it well. Schrodinger counts Bill Gates and David E. Shaw, the hedge fund...
Read More
26
Dec
2018

Messenger RNA Therapies That You May Not Have Heard Of: Ron Renaud on The Long Run

Today’s guest on The Long Run is Ron Renaud. Ron is the CEO of Lexington, Mass.-based Translate Bio. The company is working on messenger RNA therapies. You may have heard about this technology. mRNA molecules provide genetic instructions for making proteins. The idea is to restore functional proteins that, for one reason or another, have gone awry in a disease...
Read More
14
Nov
2018

From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run

Julie Sunderland is the guest on the latest episode of The Long Run podcast. She is a managing director at Biomatics Capital, a Seattle-based venture firm that invests in what it calls “data-enabled healthcare.” Before diving into that, as always, I want listeners to get to know the person making things happen, and how she got here. Sunderland her fellow...
Read More
1
Nov
2018

Exploring Synthetic Lethal Cancer Drug Discovery: Barbara Weber on The Long Run

Today’s guest on The Long Run podcast is Barbara Weber. She is the CEO of Cambridge, Mass.-based Tango Therapeutics. Ever hear the saying ‘it takes two to tango?’ That’s where this startup draws its inspiration. It’s seeking to discover and develop synthetic lethal cancer drugs. These are intended to target two molecular vulnerabilities of a cancer cell, not just one,...
Read More
17
Oct
2018

Making it Easy to Share Biological Data: John Wilbanks on The Long Run Podcast

John Wilbanks is today’s guest on The Long Run podcast. He’s the chief commons officer of Sage Bionetworks. He’s also a senior fellow with FasterCures. Sage, for those unfamiliar, is a nonprofit biomedical research organization, founded in Seattle in 2009 by a couple of veterans of Merck. Co-founders Stephen Friend and Eric Schadt recognized that no single company’s R&D labs,...
Read More
25
Jul
2018

Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast

Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...
Read More
9
May
2018

Charting His Own Entrepreneurial Course: Ethan Perlstein on The Long Run

Today’s guest on The Long Run podcast is Ethan Perlstein. He’s outspoken on social media, unafraid to occasionally rattle cages with the industry powers that be. He’s followed an unusual entrepreneurial path, starting a Public Benefit company, raising money from non-traditional sources, embracing ‘radical transparency,’ building an unusual model-organism based platform for drug discovery, and using his Internet savvy to...
Read More
25
Apr
2018

What Can You Do With Genomics and AI? Alice Zhang on The Long Run

Today’s guest on The Long Run podcast is Alice Zhang. Let’s start with some basic background. Zhang studied systems biology at Princeton, graduated with honors, enrolled in an MD/PHD program at UCLA/Caltech, stayed there five years, quit, moved to Silicon Valley, and co-founded a company dedicated to using her knowledge for neurodegenerative drug discovery. She has been named among the...
Read More
11
Apr
2018

The Immune Sequencing Frontier: Harlan and Chad Robins on The Long Run

Today on The Long Run are a pair of guests — Harlan and Chad Robins. They are the brothers who co-founded Seattle-based Adaptive Biotechnologies almost a decade ago. Chad is the CEO, and Harlan is the head of innovation. Adaptive, for those unfamiliar, has a specialized focus on sequencing regions of B-cells and T-cells of the adaptive immune system where...
Read More
14
Mar
2018

From Rock DJ to Scientist to Entrepreneur: Michael Gilman on The Long Run Podcast

Today’s guest on The Long Run podcast is Michael Gilman. He’s the CEO of a pair of Boston-area biotech startups. One is Arrakis Therapeutics, a company attempting to make small molecule drugs against RNA targets. The other is Obsidian Therapeutics, a company seeking to take the next step in CAR-T immunotherapy, by carefully controlling dosing to avoid some of the...
Read More
14
Feb
2018

Building a Cancer R&D Engine To Last: David Schenkein on The Long Run

Today’s guest on The Long Run podcast is David Schenkein. He’s the CEO of Cambridge, Mass.-based Agios Pharmaceuticals. Agios was founded a decade ago on the then-provocative idea of fighting cancer via new understanding of metabolic pathways that get hijacked by cancer cells. The company has grown up quite a bit since. It went from concept to new chemical entities...
Read More
31
Jan
2018

Big Idea, Big Money, Big Skepticism: The Long Run Podcast With Stephane Bancel

Today’s guest on The Long Run is Stephane Bancel. He’s the CEO of Cambridge, Mass.-based Moderna Therapeutics. The company, and the man at the helm, are somewhat controversial. Google Bancel’s name, and the ‘People Also Search For’ window shows famous entrepreneurs like Jeff Bezos, Elon Musk…and Elizabeth Holmes of Theranos infamy. Each situation for those entrepreneurs is different, and comparisons...
Read More